FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound of formula [1] or its pharmaceutically acceptable salt, wherein R1 are R2 identical or different, and each of them represents a hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group or C1-6alkoxy group (C1-6alkyl group, C1-6alkoxy group and C3-8cycloalkyl group can be substituted by 1-3 substitutes, which are identical or different from a halogen atom, C1-6alkoxy group); R3 represents a hydrogen atom or C1-6alkyl group; R4 represents a hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group (which can be substituted by substitutes specified in the patent claim), a heterocyclic group specified in pyridine; A1 represents a bivalent aryl group, a bivalent heterocyclic group specified in pyridyl, pyrazinyl, thiophenyl, or C3-8cycloalkylene group (bivalent aryl group can be substituted by 1-4 substitutes, which are identical or different from the following group of substitutes Ra, which are specified in the patent claim); L represents -C≡C-, -C≡C-C≡C-, -C≡C-(CH2)m-O-, CH=CH-, -CH=CH-C≡C-, -C≡C-CH=CH-, -O-, -(CH2)m-O-, -O-(CH2)m-, C1-4alkylene group or a bond; m means 1, 2 or 3; A2 represents a bivalent aryl group, a bivalent heterocyclic group (presented in the patent claim), C3-8cycloalkylene group, C3-8cycloalkenylene group, C1-4alkylene group or C2-4alkenylene group (which can be substituted by 1-4 substitutes, which are identical or different and specified in a group of substitutes Rb, which is specified in the patent claim); W represents R6-X1-, R6-X2-Y1-X1-, R6-X4-Y1-X2-Y3-X3-, Q-X1-Y2-X3- or Q-X1-Y1-X2-Y3-X3-; Y2, Y1, Y3, n, X1, X3, X2, X4, Q, R6, R7, R8 and R9 are presented in the patent claim. The compounds of formula [1] possess antimicrobial activity on gram-negative bacteria by LpxC inhibition.
EFFECT: hydroxamic acid derivatives possessing uridyldiphospho(UDP)-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) inhibition activity.
25 cl, 107 tbl, 36 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONDENSED 4-OXOPYRIMIDINE DERIVATIVE | 2005 |
|
RU2358969C2 |
| NEW OCTAHYDROTHIENOQUINOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING DERIVATIVE, AND USING THEM | 2012 |
|
RU2573399C2 |
| TETRAHYDROPYRIDINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | 2017 |
|
RU2722594C1 |
| PYRAZOL DERIVATIVES, MEDICAL COMPOSITIONS, CONTAINING THEM, THEIR APPLICATION IN MEDICINE AND INTERMEDIATE COMPOUNDS FOR THEIR PRODUCTION | 2003 |
|
RU2369613C2 |
| METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | 2020 |
|
RU2820673C2 |
| PARTLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 2013 |
|
RU2641291C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND MEDICAMENTS THEREOF AS ACTIVE INGREDIENT | 2004 |
|
RU2366655C2 |
| 1,2,4-TRIAZOLONE DERIVATIVE | 2011 |
|
RU2566754C2 |
| DICARBOXYLIC ACID COMPOUND | 2014 |
|
RU2662817C2 |
| CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF | 2014 |
|
RU2695219C2 |
